A Review and an Update on the Screening of Epithelial Ovarian Cancer

Current Problems in Cancer

Volumn 30, Issue 5, 2006, Pages 203-232

  Reynolds, Evelyn A ^a   Moller, Karen A ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 72-4 ANTIGEN; CLAUDIN; COLONY STIMULATING FACTOR 1; HUMAN EPIDIDYMIS PROTEIN 4; KALLIKREIN; LYSOPHOSPHATIDIC ACID; MESOTHELIN; OSTEOPONTIN; OVX1 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; FAMILY HISTORY; HEREDITY; HIGH RISK POPULATION; HUMAN; OVARY CANCER; OVULATION; PENETRANCE; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY;

FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33748803607     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2006.06.001     Document Type: Article

References (58)

1. American Cancer Society. Cancer Facts and Figures 2006. Available from: http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf
2. National Cancer Institute. Cancer Stat Fact Sheets: Cancer of the Ovary. Available from: http://seer.cancer.gov/csr/1975_2003/results_merged/sect_21_ovary.pdf
3. Berek J.S. Epithelial ovarian cancer. In: Berek J.S., and Hacker N.F. (Eds). Practical Gynecologic Oncology. Third Edition (2000), Lippincott Williams & Wilkins, Philadelphia, PA 457-522
4. Goff B.A., Mandel L., Muntz H.G., and Melancon C.H. Ovarian carcinoma diagnosis: Results of a national ovarian cancer survey. Cancer 89 (2000) 2068-2075
5. Prat J., Ribe A., and Gallardo A. Hereditary ovarian cancer. Hum Pathol 36 (2005) 861-870
6. Bandera C.A. Advances in the understanding of risk factors for ovarian cancer. J Reprod Med 50 6 (2005) 399-406
7. La Vecchia C. Epidemiology of ovarian cancer: a summary review. Eur J Cancer Prev 10 (2001) 125-129
8. Zografos G.C., Panou M., and Panou N. Common risk factors of breast and ovarian cancer: recent review. Int J Gynecol Cancer 14 (2004) 721-740
9. Modugno F. Ovarian cancer and high-risk women: implications for prevention, screening, and early detection. Gynecol Oncol 91 (2003) 15-31
10. Holschneider C.H., and Berek J.S. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19 (2000) 3-10
11. Franceschi S., Parazzini F., and Negri E. Pooled anyalysis of 3 European case-control studies of epithelial ovarian cancer. III. Oral contraceptive use. Int J Cancer 49 (1991) 61-65
12. Rodriguez C., Patel A.V., Calle E.E., and Jacob E.J. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of U.S. women. J Am Med Assoc 285 (2000) 1460-1465
13. Ness R.B., Cramer D.W., Goodman M.T., Kjaer S.K., Mallin K., Mosgaard B.J., et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 155 (2002) 217-224
14. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90 (1998) 1774-1786
15. Helzlsouer K.J., Alberg A.J., Gordon G.B., Longcope C., Bush T.L., Hoffman S.C., et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. J Am Med Assoc 274 (1995) 1926-1930
16. Whysner J., and Mohan M. Perineal application of talc and cornstarch powders: evaluation of ovarian cancer risk. Am J Obstet Gynecol 182 (2000) 720-724
17. Strong K., Wald N., Miller A., and Alwan A. Current concepts in screening for noncommunicable disease: World Health Organization Consultation Group report on methodology of noncommunicable disease screening. J Med Screen 12 (2005) 12-19
18. ACOG Committee on Gynecologic Practice. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. ACOG Committee Opinion No. 280. Obstet Gynecol 100 (2002) 1413-1416
19. U S. Preventive Services Task Force. Screening for ovarian cancer: recommendation statement. Am Fam Physician 71 4 (2005) 759-762
20. Bast R.C., Feeney M., Lazarus H., and Nadler L.M. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68 (1981) 1331-1337
21. Verheijen R.H.M., von Mensdorff-Pouilly S., van Kamp G.J., and Kenemans P. CA125: fundamental and clinical aspects. Semin Cancer Biol 9 (1999) 117-124
22. Whitehouse C., and Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol 88 (2003) S152-S157
23. Menon U., Skates S.J., Lewis S., Rosenthal A.N., Rufford B., Sibley K., et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23 31 (2005) 7919-7926
24. United Kingdom Collaborative Trial of Ovarian Cancer Screening. Available from: http://www.ukctocs.org.uk/fact.htm
25. Jacobs I., Davies A.P., Bridges J., Stabile I., Fay T., Lower A., et al. Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography. Br Med J 306 6884 (1993) 1030-1034
26. Jacobs I.J., Skates S.J., MacDonald N., Menon U., Rosenthal A., Davies A.P., et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet 353 (1999) 1207-1210
27. Menon U., Skates S.J., Lewis S., Rosenthal A.N., Rufford B., Sibley K., et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23 (2005) 7919-7926
28. Buys S.S., Partridge E., Greene M.H., Prorok P.C., Reding D., Riley T.L., et al. Ovarian cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 193 (2005) 1630-1639
29. Olivier R.I., Lubsen-Brandsma M.A.C., Verhoef S., and van Buerden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 100 (2006) 20-26
30. Cohen L.S., Escobar P.F., Scharm C., Glimco B., and Fishman D.A. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 82 (2001) 40-48
31. Guerriero S., Ajossa S., Risalvato A., Lai M.P., Mais V., Angiolucci M., et al. Diagnosis of adnexal malignancies by using color Doppler energy imaging as a secondary test in persistent masses. Ultrasound Obstet Gynecol 11 (1998) 277-282
32. Guerriero S., Ajossa S., and Melis G.B. Is three-dimensional power Doppler ultrasound better than two-dimensional power Doppler?. Gynecol Oncol 84 (2002) 352-353
33. Bast R.C., Badgwell D., Lu Z., Marquez R., Rosen D., Liu J., et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15 S3 (2005) S274-S281
34. Posadas E.M., Davidson B., and Kohn E.C. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Curr Opin Oncol 16 (2004) 478-484
35. Rapkiewicz A.V., Espina V., Petricoin E.F., and Liotta L.A. Biomarkers of ovarian tumours. Eur J Cancer 40 (2004) 2604-2612
36. Stevens E.V., Liotta L.A., and Kohn E.C. Proteomic analysis for early detection of ovarian cancer: a realistic approach?. Int J Gynecol Cancer 13 suppl 2 (2003) S133-S139
37. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
38. Kong F., White C.N., Xiao X., Feng Y., Xu C., He D., et al. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol Oncol 100 (2006) 247-253
39. Zhang Z., Bast R.C., Yu Y., Sokoll L.J., and Rai A.J. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64 (2004) 5882-5890
40. Klug T.L., Sattler M.A., Colcher D., and Schlom J. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA71) on a novel pancarcinoma antigen (TAG72). Int J Cancer 38 (1986) 661-669
41. Fayed S.T., Ahmad S.M., Kassim S.K., and Khalifa A. The value of CA125 and CA72-4 in management of patients with epithelial ovarian cancer. Disease Markers 14 (1998) 155-160
42. Hasholzner U., Baumgrtner L., Steiber P., Meier W., Reiter W., Pahl H., et al. Clinical signficiance of the tumor markers CA125 II and CA72-4 in ovarian carcinoma. Int J Cancer 69 (1996) 329-334
43. Woolas R.P., Conaway M.R., Xu F., Jacobs I.J., Yu Y., Daly L., et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 59 (1995) 111-116
44. Schutter E.M.J., Sohn C., Kristen P., Mobus V., Crombach G., Kaufmann M., et al. Estimation of the probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA125, and serum CA72-4 in postmenopausal women with a pelvic mass: an international multicenter study. Gynecol Oncol 69 (1998) 56-63
45. Kim J.-H., Skates S.J., Uede T., Wong K.-k., Schorge J.O., Feltmate C., et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 287 13 (2002) 1671-1679
46. Rosen D.G., Wang L., Atkinson J.N., Yu Y., Lu K.H., Diamandis E.P., et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99 (2005) 267-277
47. Brakora K.A., Lee H., Yusuf R., Sullivan L., Harris A., Colella T., et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 93 (2004) 361-365
48. Schorge J.O., Drake R.D., Lee H., Skates S.J., Rajanbabu R., Miller D.S., et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 10 (2004) 3474-3478
49. van Haaften-Day C., Shen Y., Xu F., Yu Y., Berchuck A., Havrilesky L.J., et al. OVX1, macrophage-colony stimulating factor, and CA125II as tumor markers for epithelial ovarian carcinoma. Cancer 92 11 (2001) 2837-2844
50. Xu F.-J., Ramakrishnan S., Daly L., Soper J.T., Berchuck A., Clarke-Pearson D., et al. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 165 (1991) 1365-2
51. Gadducci A., Ferdeghini M., Castellani C., Annicchiarico C., Prontera C., Facchini V., et al. Serum macrophage colony-stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer. Gynecol Oncol 70 (1998) 111-114
52. Woolas R.P., Xu F.-J., Jacobs I.J., Yu Y.-H., Daly L., Berchuck A., et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 85 (1993) 1748-1751
53. Xu Y., Shen Z., Wiper D.W., Wu M., Morton R.E., Elson P., et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. J Am Med Assoc 280 8 (1998) 719-723
54. Sutphen R., Xu Y., Wilbanks G.D., Fiorica J., Grendys E.C., LaPolla J.P., et al. Lysophopholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13 7 (2004) 1185-1191
55. McIntosh M.W., Drescher C., Karlan B., Scholler N., Urban N., Hellstrom K.E., et al. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 95 (2004) 9-15
56. Drapkin R., von Horsten H.H., Lin Y., Mok S.C., Crum C.P., Welch W.R., et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65 6 (2005) 2162-2169
57. Hellstrom I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A., Schummer M., McIntosh M., et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63 (2003) 3695-3700
58. Rosen D.G., Wang L., Atkinson J.N., Yu Y., Lu K.H., Diamandis E.P., et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99 (2005) 267-277